anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite (see CLINICAL PHARMACOLOGY, Drug Interactions). In humans, two inhibitors of P450 3A4 have been studied. Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration. Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration. The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined. Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9. These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.

As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.

Lithium:

As with other drugs which affect the excretion of sodium, lithium excretion may be reduced. Therefore, serum lithium levels should be monitored carefully if lithium salts are to be co-administered with angiotensin II receptor antagonists.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including losartan) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving losartan and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including losartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.

Dual Blockade of the Renin-Angiotensin System (RAS)

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patients on losartan potassium and other agents that affect the RAS.

Do not co-administer aliskiren with losartan potassium tablets in patients with diabetes. Avoid use of aliskiren with losartan potassium tablets in patients with renal impairment (GFR <60 mL/min).
Interleukin-10 (IL-10) is an immunomodulatory cytokine that plays a pivotal role in the pathogenesis of acute coronary syndromes (ACS). Here, we evaluated the role of IL10 promoter variants as markers for ACS susceptibility in Western Mexican patients as well as its association with IL10 mRNA and IL-10 plasma levels. Three promoter variants (- 1082 A > G, - 819 T > C and - 592 A > C) were analyzed in 300 ACS patients and 300 control group (CG) individuals. IL10 relative gene expression was evaluated in peripheral blood mononuclear cells (PBMC) and IL-10 levels were quantified in plasma. The allelic, genotypic and haplotypic frequencies did not show significant differences between groups. ACS patients had sevenfold higher mRNA IL10 level compared to CG (p = 0.0013). Homozygous C/C carriers in both - 819 T > C and - 592 A > C variants had 0.4-fold higher IL10 mRNA expression than heterozygous and polymorphic allele homozygous genotypes (p = 0.0357) in ACS group. There were significant differences in plasma IL-10 levels in CG and ACS group (1.001 vs 1.777 pg/mL, p = 0.0051). The variants were not markers of susceptibility to ACS in Western Mexican individuals. ACS patients showed higher IL10 expression than CG individuals which could be mediated by - 819 T > C and - 592 A > C variants and pharmacotherapy.
The invention comprises organophosphorus compounds of the general formula <FORM:1007332/C2/1> wherein R1 and R2 are the same or different and each is a C1-C2 alkyl group, each of which is substituted with one halogen atom (e.g. Cl or Br), X is an O or S atom and Y1 and Y2 are the same or different and each is a hydrogen or halogen atom or a C1-C4 alkyl group or a benzyl or phenyl group optionally substituted in the ring with one or more members of the group consisting of halogen atoms, nitro group and C1-C4 alkyl groups or or Y1 and Y2 together form a C3-C6 alkylene chain.  They may be obtained by reacting a compound of the formula <FORM:1007332/C2/2> with a coumarin compound of the formula <FORM:1007332/C2/3> wherein Z is a halogen atom, preferably Cl, and M is a hydrogen atom or an alkali metal atom.  The reaction when M is hydrogen is preferably carried out with the heating in the presence of an acid binding agent, e.g. an alkali metal carbonate or an organic base, and of a solvent such as acetone, ethylmethylketone, methyl propyl ketone, toluene, CCl4 or benzene and of a catalyst, e.g. finely-divided copper.  The compounds in which X is oxygen may also be prepared by reacting a compound of formula II wherein Z is H with a compound of formula III wherein M is also H in the presence of a polyhalogenated aliphatic hydrocarbon oxidizing agent and an acid binding agent, e.g. an alkali metal carbonate or pyridene, preferably at between 10 DEG and 50 DEG  C.  The oxidizing agent may be carbon tetrachloride in which case it may also act as solvent medium or it may be carbon tetrabromide in which case a solvent such as benzene may also be incorporated in the reaction mixture.  The products have nematocidal properties (see Division A5).ALSO:A nematocidal formulation comprises a phosphorus compound of the formula:-  <FORM:1007332/A5-A6/1> wherein R1 and R2 are the same or different and each is a C1-C6 monohaloalkyl radical, X is an O or S atom and Y1 and Y2 are the same or different and each is hydrogen, a halogen atom, a C1-Cx alkyl group or a benzyl or phenyl group optionally substituted in the ring with one or more members of the group consisting of halogen atoms, nitro group and C1-C4 alkyl groups or Y1 and Y2 together form a C3-C6 alkylene chain (see Division C2) and an acceptable carrier therefor. The formulation may be presented in the form of a dispersible or wettable powder for administration as a drench in water, as capsules or cachets in the dry state, as an aqueous solution, as a non-aqueous suspension which may contain a gelling or suspending agent, in tablet form, or as a water, oil or water/oil emulsion which may also contain a flavouring, preserving or thickening agent or may be added to a food.  Other biologically active substances may also be present, e.g. phenothiazine or bephenium hydroxynaphthoate.
BACKGROUND: Obesity is characterized by excessive fat accumulation in the body. Physical activity (PA) is an effective intervention to combat obesity, but the effectiveness of different PA patterns on controlling obesity is unclear. Lipid accumulation product (LAP), derived from waist circumference and triglycerides, is a novel indicator for obesity evaluation. However, the association between PA patterns (i.e., weekend warriors and regularly active) and LAP remains unexplored. This study aims to elucidate the relationship between PA patterns and LAP in US adult population.
METHODS: Adult individuals with complete data on LAP, PA patterns, and other covariates from the National Health and Nutrition Examination Survey (NHANES) database (2007-2018) were included in this study. Multivariate linear regression models were utilized to explore the association between PA patterns and LAP. Subgroup analyses, interaction tests, restricted cubic spline (RCS) regression analyses, and threshold and saturation effect analyses were also performed to investigate the stability and nonlinearity of PA-LAP association, respectively.
RESULTS: A total of 11,212 participants were included in this study. After adjusting for all potential covariates, being regularly active (RA) (β=-8.85, P < 0.05) obtained significantly higher LAP reduction as opposed to being weekend warriors (WWs) (β=-4.70, P = 0.3841). Furthermore, subgroup analyses and interaction tests indicated that the PA-LAP association was more pronounced in individuals with higher education levels (P interaction = 0.0084) and diabetes (P interaction = 0.0062). Additionally, a significant, non-linear, and negative correlation between weekly total PA and LAP in non-inactive individuals was identified by RCS analysis (P for overall < 0.001, P for nonlinearity = 0.009). A threshold of 440 min in weekly total PA was found to arouse favorable LAP reduction.
CONCLUSIONS: Being regularly active obtained better LAP reduction as opposed to being WWs. For non-inactive adults, engaging in more than 440 min of PA per week helps to reduce LAP effectively.
The present invention relates to a biological sample quality apparatus for determining the quality of a biological sample. The apparatus includes a sample receiver for receiving the biological sample. One or more light sources are provided for supplying light to the sample. An image sensor is provided for capturing an image of the lit sample. The apparatus also includes an image processor for image processing the captured image to determine the quality of the sample. Advantageously, image processing may be used to determine the quality of a sample for use in collection sites and screening laboratories so that acceptability can be determined prior to analyzing the sample. Determination that the sample is of sufficient quality (e.g. sufficient biomaterial) prior to analyzing saves wastage of laboratory time and expense of materials and chemicals. The apparatus may be in the form of desktop or hand-held portable variations.
In the corticosteroid group (20 patients), 1 gram of methylprednisolone will be added in the priming solution of CPB machine. No filter will be installed on the CPB.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: agent has the spotted milk thistle fruit flavolignans as a liquid extract. An agent has additionally plant extract on 40% ethyl alcohol obtained at the following mass ratios: milfoil herb 3.0, not less: matricary flowers 5.0, not less; coriander fruits 2.0, not less; dioecious nettle leaves 5.0, not less; knotgrass herb 5.0, not less; licorice roots 10.0, not less; medicinal Melissa 5.0, not less; tripartite bur-marigold herb 3.0, not less; pot-marigold flowers 2.0, not less and birch leaves 10.0, not less. Also, an agent has the plant extract and milk thistle liquid extract at the following mass ratio of components: milk thistle liquid extract 200.0 and plant extract liquid 100.0. Method of preparing involves two stages. On the first stage the method involves extraction of licorice roots, birch leaves, medicinal Melissa herb, milfoil herb, coriander fruits, medicinal matricary flowers, pot-marigold flowers, dioecious nettle leaves, bur-marigold herb, knotgrass herb with 40% ethyl alcohol at the room temperature. Then method involves their extraction at heating at the range 70-80 C and obtained extracts are combined. At the second stage the combined extract is added as thin jet to the milk thistle liquid extract at stirring, settled for 4-5 h and the ready product is filtered off. EFFECT: simplified technology, high pharmacological effect of the end product. 2 cl, 2 ex
Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
INTRODUCTION: Acute ischemic stroke (AIS) stands as a leading cause of death and disability globally. This study aimed to investigate the risk factors and relevance linked with AIS in patients undergoing maintenance hemodialysis (MHD) and to create and validate nomogram models.
METHODS: We examined the medical records of 314 patients with stage 5 chronic kidney disease (CKD 5) undergoing MHD, who sought neurology outpatient department consultation for suspected AIS symptoms between January 2018 and December 2023. These 314 patients were randomly divided into the training cohort (n = 222) and validation cohort (n = 92). The least absolute shrinkage selection operator (LASSO) regression model was employed for optimal feature selection in the AIS risk model. Subsequently, multivariable logistic regression analysis was used to construct a predictive model incorporating the features selected through LASSO. This predictive model's performance was assessed using the C-index and the area under the receiver operating characteristic curve (AUC). Additionally, calibration and clinical utility were evaluated through calibration plots and decision curve analysis (DCA). The model's internal validation was conducted using the validation cohort.
RESULTS: Predictors integrated into the prediction nomogram encompassed cardiovascular disease (CVD) (odds ratio [OR] 7.95, 95% confidence interval [CI] 2.400-29.979), smoking (OR 5.7, 95% CI: 1.661-21.955), dialysis time (OR: 5.91, 95% CI: 5.866-29.979), low-density lipoprotein (OR: 2.99, 95% CI: 0.751-13.007), and fibrin degradation products (OR: 5.47, 95% CI: 1.563-23.162). The model exhibited robust discrimination, with a C-index of 0.877 and 0.915 in the internal training and validation cohorts, respectively. The AUC for the training set was 0.857, and a similar AUC of 0.905 was achieved in the validation cohort. DCA demonstrated a positive net benefit within a threshold risk range of 2-96%.
CONCLUSION: The proposed nomogram effectively identifies MHD patients at high risk of AIS at an early stage. This model holds the potential to aid clinicians in making preventive recommendations.
The Control intervention consists of 1 in-person psychoeducational group session on general weight loss information and myths. Public web-resources about healthy eating and physical activity will be provided. Newsletters with similar content will be sent to promote retention.
The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
The present invention provides a method of treating cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administering to the individual the antigen presenting cells loaded with the plurality of tumor antigen peptides. The methods may be used alone or in combination with immune checkpoint inhibitors. The present invention provides precise therapeutic methods that are tailored to the individual using neoantigenic peptides or based on the mutation load in the tumor of the individual. Methods of making the activated T cells, methods of monitoring the treatment, and methods of cloning tumor-specific T cell receptors are also disclosed. The invention also provides isolated cell populations comprising the activated T cells, as well as compositions and kits useful for cancer immunotherapy.
Background: Gallstone ileus is a rare but potentially life-threatening condition resulting from the migration of gallstones into the gastrointestinal tract, which often necessitates surgical intervention. Three surgical procedures are well known and are practiced in clinical medicine; they include entero-lithotomy alone, entero-lithotomy with cholecystectomy, and enterolithotomy with fistula closure. However, there is no consensus regarding the best surgical approach as far as mortality, morbidity, and operative outcomes are concerned. The objectives of this systematic review and meta-analysis are to assess the relative efficacy and safety of these surgical procedures. Methods: A Preferred Reporting for Systematic Reviews and Meta-Analyses-compliant systematic literature review was conducted following the year 2000. Ovid MEDLINE, Embase and PubMed databases were searched using key terms gallstone, ileus, cholecystenteric fistula, cholecystocolonic fistula to identify cases. Two authors independently checked each study against the inclusion and exclusion criteria at each stage of screening and extraction. After applying the inclusion and exclusion criteria and quality assessment of the Newcastle Ottawa Scale (NOS), 10 studies involving 293 participants were included in the analysis. The quality of included studies was "moderate to high" according to the selection, comparability, and outcome criteria. Mortality and morbidity were analysed using pooled odds ratios (ORs) in the randomeffects model and fixed-effects model, and operative time using mean differences (MDs). In addition, subgroup analysis was conducted according to the type of intervention, and heterogeneity was evaluated by I 2 and π2. Results: The meta-analysis showed a significant reduction in mortality with combined enterolithotomy and cholecystectomy (OR: 2.39 [95% CI: 1.87, 3.04], I² = 33%), compared to enterolithotomy alone (OR: 3.09 [95% CI: 1.36, 7.02], I² = 69%). Morbidity was also higher in the fistula repair group (OR: 4.92 [95% CI: 3.38, 7.14], I² = 0%). Operative time was significantly longer for combined procedures, with a mean difference of 62.47 minutes [95% CI: 60.14, 64.81], in contrast to enterolithotomy alone. Subgroup differences were statistically significant, with p 0.01 for both mortality and operative time. Conclusion: This meta-analysis indicates that the combined approach of enterolithotomy and cholecystectomy has a reasonable risk benefit ratio in terms of decreasing mortality and controlling operative difficulty as compared to enterolithotomy alone or enterolithotomy with fistula repair. However, it is worth noting that the procedures that are considered as combined are characterised by longer operative time. These results provide evidence for the decisionmaking process surrounding intervention by taking into account individual features such as the presence of diseases or risks during surgery. These findings warrant additional high-quality research for the improvement of surgical approaches to manage gallstone ileus.
This study was planned to examine the effect of music therapy on the comfort levels of nurses. This study will be conducted as a randomized controlled experimental study. In the sample calculation, it was determined that for Power = 0.8 (beta = 0.2), alpha = 0.05 and effect size = 0.7, the sample size should be 66, 33 for the intervention group and 33 for the control group. In the study, data will be collected by using Descriptive Characteristics Information Form and Nurse Comfort Scale. Whether the nurses who meet the inclusion criteria will be in the intervention or control group will be determined by simple randomization. Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session. After 5 weeks, the Nurse Comfort Scale will be applied to the participants again. Research data will be analyzed in SPSS-25 package program.
Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
Dysphagia lusoria is a rare pediatric condition caused by extrinsic compression of the esophagus by an abnormal subclavian artery. The most common congenital abnormality in aortic arch development is an aberrant right subclavian artery. The retroesophageal right subclavian artery is typically symptomatic in 10-33% of cases. The patient, an 8-month-old girl with a history of early dysphagia and stridor, was diagnosed with an abnormal right subclavian artery. She was admitted to the pneumology service multiple times due to stridor, vomiting, and failure to thrive. During hospitalization at the gastroenterology service, a barium swallow and an upper digestive endoscopy indicated an abnormal right subclavian artery, which was confirmed by an Angiography CT scan. She underwent surgery at the age of sixteen months. All symptoms are resolved following surgical intervention, and the patient is still asymptomatic and in good clinical condition 12 months later. Every physician should be aware of abnormal right subclavian arteries and their clinical symptoms in children and adults in order to recognize and diagnose them early. Only an early evaluation may reduce complications such as delayed physical growth, dysphagia, and recurrent respiratory infections.
The present invention relates generally to a novel protein molecule and to derivatives, homologs, analogs, chemical equivalents and mimetics thereof capable of inducing, upregulating or otherwise facilitating the induction of an immune response to a mite and, more particularly, a mite from the family Glycyphagidae. These mites include dust mites and storage mites. The present invention also contemplates a genetic sequence encoding said protein molecule and derivatives, homologs, analogs, chemical equivalents and mimetics thereof. The present invention further provides genetic vaccines and other compositions comprising nucleic acid molecules. The protein molecule of the present invention may be regarded as a protein allergen and used alone or in combination with known allergens provides the possibility for developing more comprehensive tests for potential allergic responses. The protein allergen or its encoding sequence of the present invention are also useful, inter alia, in a range of therapeutic, prophylactic and diagnostic applications.